Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer

  • Tanja Ovcaricek Institute of Oncology Ljubljana
  • Iztok Takač University of Maribor Clinical Center Faculty of Medicine, University of Maribor
  • Erika Matos Institute of Oncology Ljubljana

Abstract

The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. Adjuvant systemic therapy reduces the risk of recurrence and death from BC. Whether the individual patient will benefit from adjuvant chemotherapy is an important clinical decision. Decisions that rely solely on clinico-pathological factors can sometimes lead to overtreatment. Multigene signatures represent a  progress in optimal selection of the high risk patients that might benefit from addition of chemotherapy to adjuvant systemic therapy. Several of these signatures are already commercially available and accepted by international guidelines, The value of Oncotype DX and MammaPrint has most extensive evidence-based support which is reviewed in this article.

 

Key words: hormone receptor positive HER-2 negative early breast cancer, adjuvant systemic therapy, multigene signatures

 

Author Biographies

Tanja Ovcaricek, Institute of Oncology Ljubljana
Department of Medical Oncolgy
Iztok Takač, University of Maribor Clinical Center Faculty of Medicine, University of Maribor
Division of Gynecology and Perinatology,
Erika Matos, Institute of Oncology Ljubljana
Department of Medical Oncolgy
Published
2019-09-20
How to Cite
Ovcaricek, T., Takač, I., & Matos, E. (2019). Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer. Radiology and Oncology, 53(3), 285-292. Retrieved from https://radioloncol.com/index.php/ro/article/view/3240
Section
Review